Combatting Bacterial Resistance in Europe View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2013-2021

FUNDING AMOUNT

109433010 EUR

ABSTRACT

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need. The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted. More... »

URL

http://cordis.europa.eu/project/rcn/203711_en.html

Related SciGraph Publications

  • 2019-12. Comparison of GeneXpert MRSA/SA ETA assay with semi-quantitative and quantitative cultures and nuc gene-based qPCR for detection of Staphylococcus aureus in endotracheal aspirate samples in ANTIMICROBIAL RESISTANCE & INFECTION CONTROL
  • 2018-12. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections in ANTIMICROBIAL RESISTANCE & INFECTION CONTROL
  • 2018-12. Finding and engaging patients and the public to work collaboratively on an acute infection microbiology research public panel in RESEARCH INVOLVEMENT AND ENGAGEMENT
  • 2018-10-30. Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls in INTENSIVE CARE MEDICINE
  • 2017-12. Determination of nasal and oropharyngeal microbiomes in a multicenter population-based study – findings from Pretest 1 of the German National Cohort in SCIENTIFIC REPORTS
  • 2017-12. Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials in CRITICAL CARE
  • 2017-12. Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU in BMC INFECTIOUS DISEASES
  • 2016-12. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review in ANTIMICROBIAL RESISTANCE & INFECTION CONTROL
  • 2016-12. De-escalation of pivotal beta-lactam in ventilator-associated pneumonia does not impact outcome and marginally affects MDR acquisition in INTENSIVE CARE MEDICINE
  • 2015-12. Stool metatranscriptomics: A technical guideline for mRNA stabilisation and isolation in BMC GENOMICS
  • 2015-12. Selective decontamination and antibiotic resistance in ICUs in CRITICAL CARE
  • 2014-10. De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU in INTENSIVE CARE MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "EUR", 
          "type": "MonetaryAmount", 
          "value": "109433010"
        }, 
        "description": "The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies.  The estimated costs of ARB are around \u20ac 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency \u201ctime to react\u201d). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need. \nThe over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections.  The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.", 
        "endDate": "2021-02-28T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.270680.b", 
          "type": "Organization"
        }, 
        "id": "sg:grant.5494223", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "5494223"
            ]
          }, 
          {
            "name": "cordis_id", 
            "type": "PropertyValue", 
            "value": [
              "203711"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "consortium", 
          "pathogens", 
          "patients", 
          "estimated cost", 
          "broad European network", 
          "EU Presidency", 
          "New Drugs", 
          "novel clinical trial designs", 
          "molecular mechanisms", 
          "innovative public-private collaborative partnership", 
          "initial set", 
          "antimicrobial resistance", 
          "biomarkers", 
          "ND4BB", 
          "registration", 
          "first project", 
          "threat", 
          "European Centre", 
          "decision", 
          "compliant clinical investigation sites", 
          "challenges", 
          "death", 
          "management", 
          "concept", 
          "better understanding", 
          "Control/European Medicines Agency", 
          "need", 
          "years", 
          "program", 
          "good clinical practice", 
          "development", 
          "clinical trials", 
          "impact", 
          "clinical development", 
          "bacterial infection", 
          "aspects", 
          "resistant organisms", 
          "robust microbiologic surveillance data", 
          "treatment", 
          "emergence", 
          "COMBACTE", 
          "bacterial resistance", 
          "antibiotic-resistant bacteria", 
          "subjects", 
          "network", 
          "discovery", 
          "addition", 
          "international government activities", 
          "analysis", 
          "novel agents", 
          "cost", 
          "antimicrobial therapy", 
          "application", 
          "clinical data", 
          "Bad Bugs", 
          "World Health Organization", 
          "prevention", 
          "new forms", 
          "rapid diagnostics", 
          "novel", 
          "Europe", 
          "time", 
          "US", 
          "aim", 
          "growth", 
          "clinical epidemiologic data", 
          "Trans-Atlantic Task Force", 
          "new treatments", 
          "investigation", 
          "global problem", 
          "disease prevention", 
          "new therapeutic options"
        ], 
        "name": "Combatting Bacterial Resistance in Europe", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.500100.4", 
            "type": "Organization"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.5494223"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T11:23", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/cordis_projects_4.xml.gz", 
        "startDate": "2013-01-01T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://cordis.europa.eu/project/rcn/203711_en.html"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.5494223'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.5494223'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.5494223'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.5494223'


     

    This table displays all metadata directly associated to this object as RDF triples.

    106 TRIPLES      19 PREDICATES      92 URIs      85 LITERALS      4 BLANK NODES

    Subject Predicate Object
    1 sg:grant.5494223 schema:about anzsrc-for:2211
    2 schema:amount Nd9e50d27495248d28b9f3d08c6cb6284
    3 schema:description The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need. The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.
    4 schema:endDate 2021-02-28T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.270680.b
    6 schema:identifier Na14f822ca1874586acb9b76fbbe695d2
    7 Nff1b34a5d60f46fe8f5e8ccd67f132ed
    8 schema:inLanguage en
    9 schema:keywords Bad Bugs
    10 COMBACTE
    11 Control/European Medicines Agency
    12 EU Presidency
    13 Europe
    14 European Centre
    15 ND4BB
    16 New Drugs
    17 Trans-Atlantic Task Force
    18 US
    19 World Health Organization
    20 addition
    21 aim
    22 analysis
    23 antibiotic-resistant bacteria
    24 antimicrobial resistance
    25 antimicrobial therapy
    26 application
    27 aspects
    28 bacterial infection
    29 bacterial resistance
    30 better understanding
    31 biomarkers
    32 broad European network
    33 challenges
    34 clinical data
    35 clinical development
    36 clinical epidemiologic data
    37 clinical trials
    38 compliant clinical investigation sites
    39 concept
    40 consortium
    41 cost
    42 death
    43 decision
    44 development
    45 discovery
    46 disease prevention
    47 emergence
    48 estimated cost
    49 first project
    50 global problem
    51 good clinical practice
    52 growth
    53 impact
    54 initial set
    55 innovative public-private collaborative partnership
    56 international government activities
    57 investigation
    58 management
    59 molecular mechanisms
    60 need
    61 network
    62 new forms
    63 new therapeutic options
    64 new treatments
    65 novel
    66 novel agents
    67 novel clinical trial designs
    68 pathogens
    69 patients
    70 prevention
    71 program
    72 rapid diagnostics
    73 registration
    74 resistant organisms
    75 robust microbiologic surveillance data
    76 subjects
    77 threat
    78 time
    79 treatment
    80 years
    81 schema:name Combatting Bacterial Resistance in Europe
    82 schema:recipient https://www.grid.ac/institutes/grid.500100.4
    83 schema:sameAs https://app.dimensions.ai/details/grant/grant.5494223
    84 schema:sdDatePublished 2019-03-07T11:23
    85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    86 schema:sdPublisher N05cde9bfc3e54570a0defbce85fdaea2
    87 schema:startDate 2013-01-01T00:00:00Z
    88 schema:url http://cordis.europa.eu/project/rcn/203711_en.html
    89 sgo:license sg:explorer/license/
    90 sgo:sdDataset grants
    91 rdf:type schema:MonetaryGrant
    92 N05cde9bfc3e54570a0defbce85fdaea2 schema:name Springer Nature - SN SciGraph project
    93 rdf:type schema:Organization
    94 Na14f822ca1874586acb9b76fbbe695d2 schema:name dimensions_id
    95 schema:value 5494223
    96 rdf:type schema:PropertyValue
    97 Nd9e50d27495248d28b9f3d08c6cb6284 schema:currency EUR
    98 schema:value 109433010
    99 rdf:type schema:MonetaryAmount
    100 Nff1b34a5d60f46fe8f5e8ccd67f132ed schema:name cordis_id
    101 schema:value 203711
    102 rdf:type schema:PropertyValue
    103 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    104 rdf:type schema:DefinedTerm
    105 https://www.grid.ac/institutes/grid.270680.b schema:Organization
    106 https://www.grid.ac/institutes/grid.500100.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...